Drug Type Monoclonal antibody |
Synonyms MIL93 |
Target |
Mechanism CLDN18.2 inhibitors(Claudin 18.2 inhibitors) |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
CLDN18.2 positive Gastrooesophageal junction cancer | Phase 2 | CN | - | |
CLDN18.2 positive Pancreatic Cancer | Phase 2 | CN | - | |
CLDN18.2 positive Stomach Cancer | Phase 2 | CN | - | |
Metastatic Solid Tumor | Phase 1 | CN | 21 Apr 2021 | |
CLDN18.2 Positive Gastrointestinal Neoplasms | IND Approval | CN | 29 Dec 2022 |
Phase 1 | 30 | mhtabqhvhj(fgpjkmwmez) = vqoldmofeo yqrikhbxog (fxdhygdpfy ) View more | Positive | 24 Jan 2023 | |||
Phase 1 | 13 | wqydurndlv(kvgndekogx) = jvucsxnvte phjtrdjezt (ngaebjkxzd ) View more | Positive | 02 Jun 2022 |